Advanced Therapies Week 2022 | Overcoming issues associated with autologous therapies

Cate Dyer, CEO & Founder, StemExpress, Folsom, CA, describes strategies to solve problems relating to manufacturing autologous therapies, which are harder to mass produce compared to allogeneic therapies. Collaboration with pharmaceutical companies and hospitals have led to on-site facilities that collect patient cells, which has enabled easier access to allogeneic therapies for patients. She additionally emphasizes the need for collaborators to provide the necessary infrastructure for hospitals to ensure reliable patients cell collection. This interview took place at Advanced Therapies Week 2022.